HK1127370A1 - Mutant vesicular stomatitis viruses and use thereof - Google Patents
Mutant vesicular stomatitis viruses and use thereofInfo
- Publication number
- HK1127370A1 HK1127370A1 HK09106370.8A HK09106370A HK1127370A1 HK 1127370 A1 HK1127370 A1 HK 1127370A1 HK 09106370 A HK09106370 A HK 09106370A HK 1127370 A1 HK1127370 A1 HK 1127370A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vesicular stomatitis
- stomatitis viruses
- mutant
- mutant vesicular
- viruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45759103P | 2003-03-27 | 2003-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1127370A1 true HK1127370A1 (en) | 2009-09-25 |
Family
ID=33098236
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05111806.6A HK1077084A1 (en) | 2003-03-27 | 2005-12-21 | Mutant vesicular stomatitis viruses and use thereof |
HK09106370.8A HK1127370A1 (en) | 2003-03-27 | 2009-07-14 | Mutant vesicular stomatitis viruses and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05111806.6A HK1077084A1 (en) | 2003-03-27 | 2005-12-21 | Mutant vesicular stomatitis viruses and use thereof |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP2039773B1 (xx) |
JP (4) | JP2007524363A (xx) |
CN (1) | CN1788088B (xx) |
AT (2) | ATE417115T1 (xx) |
AU (1) | AU2004223808B2 (xx) |
CA (1) | CA2520279C (xx) |
DE (1) | DE602004018284D1 (xx) |
DK (1) | DK1606411T3 (xx) |
ES (1) | ES2319424T3 (xx) |
HK (2) | HK1077084A1 (xx) |
IL (1) | IL171133A (xx) |
MX (1) | MXPA05010260A (xx) |
NZ (1) | NZ542902A (xx) |
WO (2) | WO2004085658A1 (xx) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1769433B (zh) * | 2004-11-04 | 2011-03-16 | 张庆勇 | 重组水疱性口炎病毒及其应用 |
CN100341571C (zh) * | 2005-09-16 | 2007-10-10 | 孙介光 | 一种治疗肿瘤的药物及该药物在制备治疗肿瘤药物中应用 |
CA2734740A1 (en) * | 2008-08-21 | 2010-02-25 | Ottawa Hospital Research Institute | Engineered synergistic oncolytic viral symbiosis |
WO2010080909A1 (en) | 2009-01-08 | 2010-07-15 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
JP5675789B2 (ja) * | 2009-06-08 | 2015-02-25 | ザ ユニバーシティー オブ ウェスタン オンタリオThe University Of Western Ontario | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 |
WO2010147971A2 (en) * | 2009-06-15 | 2010-12-23 | New York University | Il23 modified viral vector for recombinant vaccines and tumor treatment |
WO2011032003A1 (en) * | 2009-09-10 | 2011-03-17 | Yale University | Immunization to reduce neurotoxicity during treatment with cytolytic viruses |
CN102486474B (zh) * | 2010-12-06 | 2014-05-28 | 北京大学人民医院 | 干扰素治疗慢性丙型肝炎转归预测蛋白芯片 |
CA2829607A1 (en) * | 2011-03-11 | 2012-09-20 | Mcmaster University | A method of vaccination comprising a histone deacetylase inhibitor |
EP2764119A2 (en) | 2011-10-05 | 2014-08-13 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
IN2014DN05656A (xx) * | 2011-12-23 | 2015-04-03 | Univ Western Ontario | |
US20140087362A1 (en) | 2012-03-16 | 2014-03-27 | Aladar A. Szalay | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
WO2013158265A1 (en) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
CN105121636A (zh) | 2012-12-21 | 2015-12-02 | 渥太华医院研究所 | 非复制型病毒衍生颗粒及其用途 |
CA2915045A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | Compositions and methods for enhancing virus replication |
WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
KR102122463B1 (ko) | 2014-10-14 | 2020-06-15 | 할로자임, 아이엔씨 | 아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법 |
CN105087645A (zh) * | 2015-08-04 | 2015-11-25 | 上海交通大学 | M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用 |
MA43552A (fr) | 2016-04-15 | 2018-11-07 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants de cd80 et leurs utilisations |
CA3019199A1 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
CN110352245A (zh) | 2016-10-20 | 2019-10-18 | 高山免疫科学股份有限公司 | 可分泌变体免疫调节蛋白和工程化细胞疗法 |
JP2020507349A (ja) | 2017-02-09 | 2020-03-12 | インダプタ セラピューティクス インコーポレイテッド | 操作されたナチュラルキラー(nk)細胞ならびにその組成物および方法 |
CN110831963A (zh) | 2017-03-16 | 2020-02-21 | 高山免疫科学股份有限公司 | Pd-l1变体免疫调节蛋白及其用途 |
EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Pd−l2バリアント免疫調節タンパク質及びその使用 |
EP3624825A4 (en) * | 2017-05-19 | 2021-03-10 | Georgia State University Research Foundation, Inc. | RECOMBINANT ONCOLYTIC VIRUS |
AU2018351000B2 (en) | 2017-10-18 | 2023-11-30 | Alpine Immune Sciences, Inc. | Variant ICOS Ligand immunomodulatory proteins and related compositions and methods |
CN110305198B (zh) * | 2018-03-27 | 2021-01-29 | 睿丰康生物医药科技(浙江)有限公司 | 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用 |
WO2019183802A1 (zh) * | 2018-03-27 | 2019-10-03 | 苏州奥特铭医药科技有限公司 | 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用 |
US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
ES2966045T3 (es) | 2018-06-04 | 2024-04-18 | Calidi Biotherapeutics Inc | Vehículos basados en células para la potenciación de la terapia viral |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
US11655455B2 (en) | 2018-11-06 | 2023-05-23 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
US20220008466A1 (en) | 2018-11-21 | 2022-01-13 | Indapta Therapeutics, Inc | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
CN111494432A (zh) * | 2019-01-31 | 2020-08-07 | 惠君生物医药科技(杭州)有限公司 | 一种用于治疗肿瘤或癌症的药物组合物及其应用 |
CN113748124A (zh) | 2019-02-27 | 2021-12-03 | 阿克蒂姆治疗有限公司 | 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌 |
CN111662883A (zh) * | 2019-03-06 | 2020-09-15 | 惠君生物医药科技(杭州)有限公司 | 一种制备及纯化溶瘤病毒的方法及重组溶瘤弹状病毒 |
CN110305850A (zh) * | 2019-05-15 | 2019-10-08 | 苏州奥特铭医药科技有限公司 | 一种利用293细胞生产制备溶瘤病毒的方法 |
CN111939262B (zh) * | 2019-05-17 | 2021-09-17 | 睿丰康生物医药科技(浙江)有限公司 | 一种治疗肿瘤或癌症的药物组合物和其应用 |
CN111088283B (zh) * | 2020-03-20 | 2020-06-23 | 苏州奥特铭医药科技有限公司 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
US20230149536A1 (en) * | 2020-04-17 | 2023-05-18 | Vyriad, Inc. | Compositions for treating and/or preventing coronavirus infections |
KR20230088306A (ko) | 2020-04-22 | 2023-06-19 | 인답타 세라뷰틱스 인코포레이티드 | 자연 살해(nk) 세포 조성물 및 이를 생성하는 방법 |
CN111286493B (zh) | 2020-05-12 | 2020-10-27 | 上海荣瑞医药科技有限公司 | 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物 |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
CN115612674A (zh) * | 2021-07-14 | 2023-01-17 | 上海荣瑞医药科技有限公司 | 一种溶瘤病毒及其用途 |
CN115948352A (zh) * | 2022-11-29 | 2023-04-11 | 浙江迪福润丝生物科技有限公司 | 一种水泡性口炎病毒的致弱方法及致弱病毒株和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US6022726A (en) | 1992-02-03 | 2000-02-08 | Palese; Peter | Genetically engineered attenuated viruses |
GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
ATE241994T1 (de) | 1996-01-25 | 2003-06-15 | Univ Glasgow | Hsv-mutant-1716 zur behandlung von mesotheliomen |
US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
US6531123B1 (en) | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
CN1281512A (zh) | 1997-12-12 | 2001-01-24 | 昂尼克斯药物公司 | p53+肿瘤细胞的选择性杀伤和诊断 |
AP1968A (en) | 1997-12-22 | 2009-04-30 | Univ Tennessee Res Corp | Recombinant rhabdovirus containing a heterologous fusion protein. |
ATE384126T1 (de) | 1998-06-12 | 2008-02-15 | Sinai School Medicine | Interferon induzierende genetisch veränderte attenuierte viren |
US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
MXPA01010393A (es) | 1999-04-15 | 2004-04-02 | Pro Virus Inc | Tratamiento de neoplasmas con virus. |
ES2260057T3 (es) | 1999-09-17 | 2006-11-01 | Wellstat Biologics Corporation | Virus oncolitico. |
WO2001055353A2 (en) | 2000-01-26 | 2001-08-02 | Boehringer Ingelheim Vetmedica Gmbh | Recombinant attenuation of prrsv |
DE10143813A1 (de) | 2001-09-06 | 2003-04-10 | Boehringer Ingelheim Vetmed | Infektiöser Rindervirusdiarrhoe-Virusklon |
CN1820078A (zh) * | 2002-09-09 | 2006-08-16 | 田纳西大学研究基金会 | 弹状病毒的重组突变体及其应用方法 |
-
2004
- 2004-03-29 CA CA2520279A patent/CA2520279C/en not_active Expired - Fee Related
- 2004-03-29 EP EP08168529A patent/EP2039773B1/en not_active Expired - Lifetime
- 2004-03-29 CN CN2004800084162A patent/CN1788088B/zh not_active Expired - Fee Related
- 2004-03-29 NZ NZ542902A patent/NZ542902A/en not_active IP Right Cessation
- 2004-03-29 AU AU2004223808A patent/AU2004223808B2/en not_active Ceased
- 2004-03-29 WO PCT/CA2004/000460 patent/WO2004085658A1/en active Application Filing
- 2004-03-29 EP EP04723949A patent/EP1606411B1/en not_active Expired - Lifetime
- 2004-03-29 AT AT04723949T patent/ATE417115T1/de active
- 2004-03-29 ES ES04723949T patent/ES2319424T3/es not_active Expired - Lifetime
- 2004-03-29 DE DE602004018284T patent/DE602004018284D1/de not_active Expired - Lifetime
- 2004-03-29 WO PCT/CA2004/000463 patent/WO2004085659A2/en active Application Filing
- 2004-03-29 DK DK04723949T patent/DK1606411T3/da active
- 2004-03-29 AT AT08168529T patent/ATE539162T1/de active
- 2004-03-29 MX MXPA05010260A patent/MXPA05010260A/es active IP Right Grant
- 2004-03-29 JP JP2006504087A patent/JP2007524363A/ja active Pending
-
2005
- 2005-09-27 IL IL171133A patent/IL171133A/en not_active IP Right Cessation
- 2005-12-21 HK HK05111806.6A patent/HK1077084A1/xx not_active IP Right Cessation
-
2007
- 2007-03-28 JP JP2007086050A patent/JP2007215547A/ja not_active Withdrawn
-
2009
- 2009-07-14 HK HK09106370.8A patent/HK1127370A1/xx not_active IP Right Cessation
-
2011
- 2011-02-25 JP JP2011040938A patent/JP2011103897A/ja active Pending
-
2013
- 2013-08-01 JP JP2013160234A patent/JP2013247959A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2004085659A2 (en) | 2004-10-07 |
ATE539162T1 (de) | 2012-01-15 |
JP2007524363A (ja) | 2007-08-30 |
CN1788088B (zh) | 2012-09-26 |
AU2004223808A1 (en) | 2004-10-07 |
CA2520279A1 (en) | 2004-10-07 |
EP2039773A1 (en) | 2009-03-25 |
CN1788088A (zh) | 2006-06-14 |
EP2039773B1 (en) | 2011-12-28 |
ES2319424T3 (es) | 2009-05-07 |
WO2004085658A1 (en) | 2004-10-07 |
NZ542902A (en) | 2007-06-29 |
DE602004018284D1 (de) | 2009-01-22 |
JP2007215547A (ja) | 2007-08-30 |
AU2004223808B2 (en) | 2009-03-26 |
IL171133A (en) | 2011-11-30 |
CA2520279C (en) | 2012-09-04 |
JP2013247959A (ja) | 2013-12-12 |
EP1606411A1 (en) | 2005-12-21 |
ATE417115T1 (de) | 2008-12-15 |
EP1606411B1 (en) | 2008-12-10 |
WO2004085659A3 (en) | 2004-12-09 |
MXPA05010260A (es) | 2006-03-17 |
DK1606411T3 (da) | 2009-03-30 |
HK1077084A1 (en) | 2006-02-03 |
JP2011103897A (ja) | 2011-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1127370A1 (en) | Mutant vesicular stomatitis viruses and use thereof | |
FR20C1016I2 (fr) | Vaccins recombinants issu du virus de la stomatite vesiculaire dirige contre les fievres hemorragiques virales | |
HK1044708A1 (en) | Oncolytic besicular stomatitis virus | |
HUP0400882A3 (en) | Oncolytic virus therapy | |
HUP0003911A2 (hu) | Neoplazmák kezelése vírusokkal | |
DE60035778D1 (de) | Rekombinante influenzaviren zur vakzinherstellung und gentherapie | |
AU586860B2 (en) | Therapeutical application of phosphonylmethoxyalkyl adenines | |
DK0773785T3 (da) | Behandling af cancer ced hjælp af HSV-mutant | |
DE68903165D1 (de) | Rns des genoms des non-a, non-b-hepatitisvirus und antigenisches virales protein. | |
IL176500A (en) | Use of respiratory syncytial virus with a gene encoded for protein g attachment to prevent or treat pneumoviral infection | |
NO20023833D0 (no) | Modifiserte cytokiner for anvendelse i cancerterapi | |
NZ305188A (en) | DNA encoding Human Papilloma Virus (hPV)type 18 | |
DK0505763T3 (da) | Vandigt desinfektionsmiddel, dets anvendelse til inaktivering af hepatitis-B-vira, bakterielle sporer og legionella pneumophila samt desinfektionsfremgangmåder | |
NZ336804A (en) | Use of pramipexole in the treatment of restless legs syndrome | |
AU8116101A (en) | Identification of viral agents in breast ducts and antiviral therapy therefore | |
AU2003253894A1 (en) | Combination therapies with ftc for the treatment of hepatitis b virus infection | |
AU2604492A (en) | Respiratory disease vaccine for cats | |
PL363175A1 (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use | |
ATE242616T1 (de) | Ärztliches oder zahnärztliches behandlungsinstrument | |
EP1785727A3 (en) | Identification of viral agents in breast ducts and antiviral therapy therefore | |
GEP20012445B (en) | Tetrahydropyrido Compounds | |
ES2155400B1 (es) | Aparato para terapia psiquico-fisica. | |
AU2002950320A0 (en) | "Viral structural protein interactions and methods of identifying antiviral agents" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160329 |